Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
The announcement was made Monday by Paul Hudson, the company’s new chief executive officer, who said during a media call that “we as a company have probably done more than almost any other companies combined, to innovate and to transform lives in diabetes and cardiovascular. Now we need to be efficient and move our resources to areas of opportunity, unmet needs and to grow our pipeline.”
Lantus, the originator insulin glargine, is under pressure from follow-on competition, given the commercialization of Boehringer Ingelheim’s Basaglar, the first FDA-approved insulin glargine follow-on, which launched in 2016 after a lengthy patent litigation with Sanofi.
In addition, insulin as a whole has been in the center of a debate for more than a year about high drug prices. Lantus, along with Novolog and Humalog, have shown highly synchronized price increases, coinciding with some of the largest growth in drug costs. And patients have traveled to Capitol Hill to testify how the rising prices have forced them to skip doses or go without.
However, a company spokesman said Monday that Sanofi will retain a proposed biosimilar of insulin aspart (NovoLog) in its pipeline as a registration phase molecule. Data on SAR341402 was presented in 3 late-breaking poster presentations at the American Diabetes Association (ADA) 79th Scientific Sessions last June. While insulins are currently regulated as drugs and follow-ons in the US context, they will become regulated as biologics and biosimilars in March 2020.
The Wall Street Journal (WSJ) noted Monday that diabetes has been a key driver for Sanofi since 2004, when Aventis and Sanofi-Synthelabo merged. Aventis had launched Lantus 4 years prior. By 2004, it was already the most widely prescribed insulin in the country.
Lantus represents that largest share of Part D spending on insulin, according to an analysis by the Kaiser Family Foundation.
Sanofi is shifting to focus on immunotherapies in cancer treatment; the company will buy biotech Synthorx for $2.5 billion. Sanofi has fallen behind in the race to develop immunotherapies, according to the WSJ report.
In addition, it wants to focus on dupilumab (Dupixent), a drug for severe chronic rhinosinusitis with nasal polyposis, severe asthma, and moderate-to-severe atopic dermatitis. Sanofi thinks the drug could eventually generate $10 billion.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.